RGENIX to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
New York, NY – November 23, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the 32nd Annual Piper Sandler Virtual
RGENIX to Present at 2020 Stifel Virtual Healthcare Conference
New York, NY – November 04, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the 2020 Stifel Virtual Healthcare Conference at 8:40 A.M. EST on November 16, 2020. To view this virtual presentation live, register for the event here. Links
RGENIX to Present at H.C. Wainwright 22nd Annual Global Investment Conference
New York, NY – September 02, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it has been selected to present at the H.C. Wainwright 22nd Annual Global Investment
RGENIX to Present at Multiple Virtual Healthcare Investor Conferences in August
New York, NY – Aug 05, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it has been selected to present at multiple virtual healthcare investor conferences taking place during the month of August. These conferences include: LifeSci Partners Summer Symposium August 5, 2020
RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting
New York, NY - June 22, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-104, RGENIX’s lead therapy in development. RGENIX’s abstract, “Correlative